Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Ipsen Pharma
Homme Max 99 ans
Ipsen Pharma
MAJ Il y a 4 ans
A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED PROOF OF CONCEPT STUDY OF MAINTENANCE THERAPY WITH TASQUINIMOD IN PATIENTS WITH METASTATIC CASTRATE-RESISTANT PROSTATE CANCER WHO ARE NOT PROGRESSING AFTER A FIRST LINE DOCETAXEL BASED CHEMOTHERAPY
To compare the clinical efficacy (i.e. radiological progression free survival [PFS]) of tasquinimod maintenance therapy with placebo in patients with metastatic castrate-resistant prostate cancer (mCR...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Homme Max 99 ans
Ipsen Pharma GmbH
MAJ Il y a 4 ans
Phase II multi-centre, randomised, open, comparative study of the safety and efficacy of transdermal testosterone (Testim®) compared to intramuscular testosterone depot for the induction of puberty in boys with hypogonadism and delayed puberty
To compare daily transcutaneous therapy with Testim® with the standard therapy with monthly (every four weeks) testosterone depot intramuscular injections with respect to efficacy and safety.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Homme Max 99 ans
Ipsen Pharma
MAJ Il y a 4 ans
Study to assess the effects of BN82451B and how it is absorbed, distributed and eliminated in the body, when it is given for 4 weeks to men suffering from Hungtington's disease
To evaluate the safety and tolerability of BN82451B versus placebo after oral administration twice daily (bid) for 28 days in subjects with Huntington’s Disease (HD).
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Ipsen Pharma
MAJ Il y a 4 ans
Comparison of efficacy and safety of Nutropin (rhGH) associated with Increlex (rhIGF-1) vs Nutropin (rhGH) alone [COGROW]
To demonstrate a superior efficacy on height velocity (HV) of treatment with a combination of flexible rhIGF-1 dose and 0.035 mg/kg/day of rhGH, as compared to treatment with 0.035 mg/kg/day of rhGH o...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Beaufour Ipsen Pharma
MAJ Il y a 4 ans
FOLLOW-UP OF THE PHASE III, MULTICENTRE, NON COMPARATIVE, ONE SINGLE GROUP, OPEN STUDY TO ASSESS THE LONG-TERM EFFICACY AND TOLERABILITY OF PAMOATE OF TRIPTORELIN 11.25 MG IN CHILDREN WITH PRECOCIOUS PUBERTY
To assess the efficacy of triptorelin 11.25 mg with respect to the proportion of children who maintain a regression or stabilisation of sexual maturity until the end of the study.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Beaufour Ipsen Pharma
MAJ Il y a 4 ans
A phase II exploratory, ascending dose, multicentre study to investigate the pharmacodynamics, pharmacokinetics, safety and tolerability, of BIM23A760 in acromegalic patients
To investigate the pharmacodynamics (PD) of BIM 23A760, administered by single subcutaneous (s.c.) injection to acromegalic patients.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Beaufour Ipsen Pharma
MAJ Il y a 4 ans
PHASE III, MULTICENTRE, OPEN STUDY TO ASSESS THE EFFICACY AND SAFETY PROFILES OF THE CO-ADMINISTRATION OF LANREOTIDE AUTOGEL 120 MG (ADMINISTERED VIA DEEP SUBCUTANEOUS INJECTIONS EVERY 28 DAYS) AND PEGVISOMANT 40 TO 120 MG PER WEEK (ADMINISTERED VIA SUBCUTANEOUS ROUTE ONCE OR TWICE A WEEK) IN ACROMEGALIC PATIENTS FAILING TO RESPOND TO LANREOTIDE AUTOGEL 120 MG ALONE
To assess the efficacy of the co-administration of lanreotide Autogel 120 mg (administered via deep subcutaneous injections every 28 days) and pegvisomant (administered at 40 to 120 mg per week via su...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Ipsen Pharma
MAJ Il y a 4 ans
PHASE II, OPEN, RANDOMISED, PARALLEL GROUP, NONCOMPARATIVE MULTICENTRE STUDY TO ASSESS THE EFFICACY AND SAFETY OF REPEATED SUBCUTANEOUS (S.C.) ADMINISTRATION OF DIFFERENT DOSES OF BIM 23A760 IN ACROMEGALIC PATIENTS
Part A: To assess the efficacy of repeated s.c. injections at different doses of BIM 23A760 on growth hormone (GH) and insulin-like growth factor-1 (IGF-1) levels in acromegalic patients after 6 month...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Beaufour Ipsen Pharma
MAJ Il y a 4 ans
Phase IIIB, international, single group, open study to define an optimal monitor-ing of IGF-I in children treated with NutropinAq™, using a novel capillary blood collection method
The number of capillary blood spot IGF-I measurements and the optimal timing of samples to assess the IGF-I status of NutropinAq treated patients.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Beaufour Ipsen Pharma-Ipsen Biotech Department
MAJ Il y a 4 ans
Phase III multicentre, Randomised, Double Blind, Comparative study to assess the efficacy and safety of lanreotide 30mg versus placebo as a palliative treatment of clinical symptoms associated with intestinal obstruction due to peritoneal carcinomatosis in inoperable patients
The primary objective of this study is to assess the efficacy of lanreotide 30 mg as compared to placebo to relieve clinical symptoms due to small bowel obstruction in inoperable patients with periton...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
1
2
3
Suivant